![](/images/graphics-bg.png)
Plasma Brain-Derived Neurotrophic Factor as a Biomarker for the Main Types of Mild Neurocognitive Disorders and Treatment Efficacy: A Preliminary Study
المؤلفون المشاركون
Trailin, Andriy V.
Levada, Oleg A.
Cherednichenko, Nataliya V.
Troyan, Alexandra S.
المصدر
العدد
المجلد 2016، العدد 2016 (31 ديسمبر/كانون الأول 2016)، ص ص. 1-7، 7ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2016-08-11
دولة النشر
مصر
عدد الصفحات
7
التخصصات الرئيسية
الملخص EN
Decreased levels of brain-derived neurotrophic factor (BDNF) are assumed to play a crucial role in the pathophysiology of mild neurocognitive disorders (MNCDs).
In this study, we compared plasma BDNF levels (at baseline and after two months of treatment with escitalopram) in patients with the main types of MNCDs and normal controls.
21 patients met the DSM-5 diagnostic criteria for possible MNCD due to Alzheimer’s disease (MNCD-AD); 22 patients fulfilled the diagnostic criteria for subcortical vascular MNCD (ScVMNCD) according to Frisoni et al.
(2002) and neuroimaging-supported probable diagnosis of vascular MNCD according to DSM-5; 16 subjects entered control group.
At baseline, we detected lower BDNF levels in both MNCD groups, which was significant only in subjects with MNCD-AD.
Moreover, plasma BDNF level of 21160 pg/mL showed high sensitivity (94%) to discriminate patients with MNCD-AD.
Decreased plasma BDNF highly correlated with the severity of memory impairment and total MMSE score in MNCD-AD group.
Escitalopram treatment in patients with MNCD-AD or ScVMNCD led to an increase of plasma BDNF concentrations and as a result to a decrease of cognitive, depressive, and anxiety symptom severity.
In conclusion, plasma BDNF might be a reliable biomarker for the validation of MNCD-AD diagnosis and treatment efficacy.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Levada, Oleg A.& Cherednichenko, Nataliya V.& Trailin, Andriy V.& Troyan, Alexandra S.. 2016. Plasma Brain-Derived Neurotrophic Factor as a Biomarker for the Main Types of Mild Neurocognitive Disorders and Treatment Efficacy: A Preliminary Study. Disease Markers،Vol. 2016, no. 2016, pp.1-7.
https://search.emarefa.net/detail/BIM-1103701
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Levada, Oleg A.…[et al.]. Plasma Brain-Derived Neurotrophic Factor as a Biomarker for the Main Types of Mild Neurocognitive Disorders and Treatment Efficacy: A Preliminary Study. Disease Markers No. 2016 (2016), pp.1-7.
https://search.emarefa.net/detail/BIM-1103701
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Levada, Oleg A.& Cherednichenko, Nataliya V.& Trailin, Andriy V.& Troyan, Alexandra S.. Plasma Brain-Derived Neurotrophic Factor as a Biomarker for the Main Types of Mild Neurocognitive Disorders and Treatment Efficacy: A Preliminary Study. Disease Markers. 2016. Vol. 2016, no. 2016, pp.1-7.
https://search.emarefa.net/detail/BIM-1103701
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1103701
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)